Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Centessa Pharmaceuticals Plc ADR (CNTA)

Centessa Pharmaceuticals Plc ADR (CNTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,130,206
  • Shares Outstanding, K 154,569
  • Annual Sales, $ 15,000 K
  • Annual Income, $ -197,530 K
  • EBIT $ -208 M
  • EBITDA $ -206 M
  • 60-Month Beta 1.25
  • Price/Sales 407.34
  • Price/Cash Flow N/A
  • Price/Book 10.09

Options Overview Details

View History
  • Implied Volatility 12.57% (-1.14%)
  • Historical Volatility 113.22%
  • IV Percentile 2%
  • IV Rank 0.86%
  • IV High 219.48% on 10/27/25
  • IV Low 10.78% on 04/09/26
  • Expected Move (DTE 25) 0.81 (2.04%)
  • Put/Call Vol Ratio 0.81
  • Today's Volume 2,167
  • Volume Avg (30-Day) 2,231
  • Put/Call OI Ratio 1.72
  • Today's Open Interest 41,623
  • Open Int (30-Day) 23,631
  • Expected Range 38.85 to 40.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 3
  • High Estimate $-0.36
  • Low Estimate $-0.39
  • Prior Year $-0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.17 +57.57%
on 03/24/26
40.26 -1.49%
on 03/31/26
+10.71 (+36.99%)
since 03/17/26
3-Month
21.50 +84.47%
on 01/20/26
40.26 -1.49%
on 03/31/26
+17.46 (+78.65%)
since 01/16/26
52-Week
10.95 +262.19%
on 06/05/25
40.26 -1.49%
on 03/31/26
+27.36 (+222.57%)
since 04/17/25

Most Recent Stories

More News
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KZR : 7.33 (-0.54%)
CNTA : 39.66 (+0.33%)
APLS : 40.90 (+0.07%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS

NEW YORK , April 8, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of...

AFBI : 22.39 (+0.13%)
KZR : 7.33 (-0.54%)
CNTA : 39.66 (+0.33%)
APLS : 40.90 (+0.07%)
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KORE : 9.14 (-0.11%)
CNTA : 39.66 (+0.33%)
APLS : 40.90 (+0.07%)
The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

NVDA : 201.68 (+1.68%)
$SPX : 7,126.06 (+1.20%)
CNTA : 39.66 (+0.33%)
LLY : 927.03 (+2.55%)
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

CNTA : 39.66 (+0.33%)
LLY : 927.03 (+2.55%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)

NEW YORK , April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions...

CNTA : 39.66 (+0.33%)
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals...

CNTA : 39.66 (+0.33%)
LLY : 927.03 (+2.55%)
Stocks Surge on Signs the US and Iran Seek to End War

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +2.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.43%. June E-mini...

ALK : 45.40 (+10.33%)
GOOGL : 341.68 (+1.68%)
AAPL : 270.23 (+2.59%)
SNDK : 920.99 (+0.17%)
ADI : 371.45 (+4.99%)
CNTA : 39.66 (+0.33%)
OXY : 53.79 (-5.42%)
TSLA : 400.62 (+3.01%)
STX : 547.75 (+3.00%)
WDC : 372.52 (+2.99%)
SPY : 710.14 (+1.21%)
META : 688.55 (+1.73%)
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders

MILWAUKEE , March 31, 2026 /PRNewswire/ -- LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with...

CNTA : 39.66 (+0.33%)
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

BIRD : 10.80 (-1.01%)
CNTA : 39.66 (+0.33%)
APLS : 40.90 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 40.05
2nd Resistance Point 39.86
1st Resistance Point 39.76
Last Price 39.66
1st Support Level 39.48
2nd Support Level 39.29
3rd Support Level 39.19

See More

52-Week High 40.26
Last Price 39.66
Fibonacci 61.8% 29.06
Fibonacci 50% 25.60
Fibonacci 38.2% 22.15
52-Week Low 10.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.